WESTLAKE VILLAGE, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments ...
Please provide your email address to receive an email when new articles are posted on . Cal/BDP is a combination formula, comprised of calcipotriol and betamethasone dipropionate, that treats ...
TORONTO, Oct. 21, 2024 /CNW/ - Arcutis Canada Inc., a commercial-stage company focused on delivering meaningful innovations in immuno-dermatology, is pleased to announce that Health Canada has ...
Supplement to a New Drug Submission supported by positive Phase 2 and Phase 3 pivotal trial efficacy and safety results TORONTO, Jan. 8, 2024 /CNW/ - Arcutis Canada Inc., an early commercial-stage ...
Collaborative partnerships can foster success in formulation development projects. The formulation development outsourcing market is expected to grow at a compound annual rate of 7.2% between 2021 and ...
The Food and Drug Administration (FDA) announced that it has accepted the supplemental New Drug Application (sNDA) for roflumilast foam 0.3% in adults and adolescents with scalp and body psoriasis ...
All pharmaceutical products are formulated to specific dosage forms for drugs to be effectively delivered to patients. Typical pharmaceutical dosage forms include oral tablets, capsules, solutions, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results